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 Myopia, the most common visual defect, affects about
30% (3%-84%) of people [1-4]. Its extreme form, high myo-
pia, affects 1%-2% of the total population. It is the fourth most
common cause of blindness because of its association with
vision-threatening conditions such as chorioretinal degenera-
tion, retinal detachment and glaucoma. High myopia can be
inherited as an autosomal dominant, autosomal recessive, X-
linked recessive or possibly complex trait. Most high myopia
is simple (non-syndromic) without other accompanied ocular
or systemic abnormalities. No genes responsible for non-
syndromic high myopia have been identified although several
chromosome loci have been assigned [5-12]. Syndromic high
myopia has been observed in Cohen syndrome (OMIM
216550), Knoblock syndrome (OMIM 267750), Stickler syn-
drome (type 1, OMIM 108300; type 2, OMIM 604841), Marfan
syndrome (OMIM 154700), RP2 (OMIM 312600), and
CSNB1 (OMIM 310500). Of these, CSNB1 is the only dis-
ease with functional defects without gross structural abnor-
malities. Several genes causing syndromes including high
myopia have been identified, including COH1, COL18A1,
COL2A1, COL11A1, FBN1, BFSP2, RP2, and NYX [13-21].
However, no mutation in any of these genes has been shown
to cause isolated high myopia.
The human NYX gene (OMIM 300278) encodes a small
leucine-rich protein (nyctalopin) with 481 amino acid resi-
dues [18,19,22]. The exact function of nyctalopin is still un-
known. Mutations in NYX have been reported to cause con-
genital stationary night blindness (CSNB1) [18,19,23-28].
Patients described with CSNB1 usually have myopia (OMIM
310500). Phenotype analysis of patients with mutations in the
NYX gene further documented that myopia in these patients
is associated with the complete form of CSNB1 [28-30]. While
mutations in the NYX gene might alter eyeball growth sec-
ondarily to their effects on rod function and vision, they might
also be associated with refraction directly in addition to their
effect on night vision. This suggests the possibility that some
mutations in NYX could cause isolated myopia without night
blindness, making it a reasonable candidate gene for isolated
X-linked myopia. We report here novel mutations in the NYX
genes in two unrelated male individuals with myopia alone
without night blindness.
METHODS
Patients with high myopia:  Unrelated probands with high
myopia were collected from the Zhongshan Ophthalmic Cen-
ter as part of a project to identify genetic loci and genes for
high myopia. Informed consent conforming to the tenets of
the Declaration of Helsinki was obtained from the participat-
ing individuals prior to the study and the study was approved
by the Institutional Review Boards of the Zhongshan Oph-
thalmic Center and the National Eye Institute. The diagnostic
criteria for high myopia were basically as previously described
[12]: (1) Myopia was noted before school age; (2a) bilateral
cycloplegic refraction of -6.00D or lower (spherical equiva-
lent) in individuals <30 years of age, or (2b) manifest refrac-
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330tion of -6.00D or lower (spherical equivalent) in individuals
30 years or more of age; and (3) Exclusion of other known
ocular or systemic diseases. Standard ophthalmological ex-
aminations including visual acuity, slit-lamp and funduscopic
examinations on all subjects and ERG, A-scan, B-scan, and
fundus photography on selected patients were performed by
ophthalmologists. Electroretinogram (ERG) responses were
recorded according to ISCEV standards [31]. Genomic DNA
was collected from 316 unrelated probands with high myopia.
Any available first-degree family members were enrolled in
the study if they agreed to participate. Of these families, 52
male probands were enrolled in the current study, after exclu-
sion of those families in which high myopia is inherited as an
autosomal trait by examination of the pedigree. Thus, while
not all individuals included in the study necessarily have X-
linked high myopia, the probands will be enriched for this
group in so far as families with identifiable autosomal inherit-
ance patterns have been excluded.
Mutation screening of candidate genes:  DNA fragments
encompassing the coding exons and the adjacent intronic se-
quence in the NYX gene (NCBI human genome build 35.1,
NC_000023 for genomic DNA, NM_022567 for mRNA,
NP_072089 for protein) of the 52 unrelated probands with
high myopia were amplified by polymerase chain reaction,
using five pairs of primers as previously described [28].
DNA was sequenced using an ABI BigDye Terminator
cycle sequencing kit v3.1 and electrophoresed on an ABI 3100
Genetic Analyzer. Variations in NYX were verified by ana-
lyzing 232 control individuals as well as family members for
whom genomic DNA was available. The controls were of
Chinese origin, living in Southern China.
Molecular modeling:  The model of the nyctalopin gene
wild type protein (nyc) was built by homology modeling based
on crystal coordinates for the Nogo receptor ectodomain
Brookhaven protein database (PDB) [32] file: 1ozn.pdb as the
structural template. The primary sequences of nyctalopin and
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Figure 1. Pedigrees, haplotyes, and sequencing results of the two families with high myopia and NYX mutations.  Filled squares represent
individuals affected with high myopia. Haplotype analysis in Family A demonstrated that the c.144C>G mutation in III:1 is a de novo muta-
tion. +: Mutation detected in II:1 of family B. Mut-F or Mut-R: Forward or Reverse sequencing of NYX gene fragments for individual III:1 in
family A (left column) and individual II:1 in family B (right column). Wild: Forward sequencing of the corresponding fragments in normal
control.
3311ozn were aligned by the method of Needleman and Wunch
[33], incorporated in the program Look, version 3.5.2 (Lee,
1993) for 3-dimensional structure prediction. Finally, the mo-
nomeric nyc was built using the automatic segment matching
method in the program Look [34] followed by 500 cycles of
energy minimization. The same program was used to gener-
ate conformation of genetic point mutations C48W and R191Q,
and then to refine it by self-consistent ensemble optimization
[35], which applies statistical mechanical mean-force approxi-
mation iteratively to achieve the global energy minimum struc-
ture. The geometry of the predicted structures was tested us-
ing the program Procheck [36].
RESULTS &  DISCUSSION
 Mutations in NYX, c.144C>G and c.572-573GC>AA, were
identified in 2 of the 52 probands, respectively. A de novo
c.144C>G mutation was found in individual III:1 in family A
(Figure 1). At the time of this study, the proband was 8 years
old, with a prescription of -12D in both eyes with a history of
having developed high myopia over -6D by 2 years of age.
There are no signs of night blindness, and the patient and his
family gave a history of normal vision at night, including be-
ing able to walk under dim light or walk upstairs or down-
stairs at night without stairway lights, just as well as his par-
ents. Both his parents had normal vision, including night vi-
sion and neither was myopic. An ERG is not available for this
individual and he and his family are not available for further
examination. The corrected visual acuity is 20/40. There was
neither nystagmus nor indication of abnormal color vision.
The refraction for other family members examined in family
A was between +1D to -1.5D. This mutation was not detected
in any other family member (Figure 1, family A).
 A c.572-573GC>AA mutation was found in a 46 year-
old man (Figure 1, II:1 in family B) with myopia of -6.50D
bilaterally. He was first diagnosed with high myopia at the
age of 40, although the condition might well have been present
before that. His phenotype has been stable since that time. His
corrected visual acuity was 20/20 at a recent examination. Oph-
thalmological examination revealed fundus changes typical
of high myopia including an optic nerve head crescent and a
“tigroid” appearance of the posterior retina, but no signs of
retinal degeneration (Figure 2). Nystagmus was not observed
and there was normal color vision. He has no difficulty walk-
ing under dim light as compared with his parents and friends.
ERGs under scotopic and photopic conditions demonstrate a
normal rod response and mildly reduced cone responses, but
no signs of the rod dysfunction seen in CSNB1. Specifically,
the rod response and bright-flash cone-rod mixed ERG am-
plitudes were normal (Table 1, Figure 3). The patterns of his
ERG responses are completely different from CSNB1 patients
with NYX mutations [28], but are similar to those of patients
with X-linked recessive high myopia[12]. His parents had
neither myopia nor CSNB.
Both the c.144C>G and c.572-573GC>AA mutations
would result in missense changes of the encoded amino acids,
Cys48Trp and Arg191Gln. These two amino acids are con-
served between human and mouse NYX [37] but are not con-
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Figure 2. Fundus photographs.  Typical changes of high myopia, including optic nerve head crescent and “tigroid” appearance of the posterior
retina, were demonstrated.
TABLE 1. ROD AND CONE RESPONSES OF II:1 ON ERG RECORDINGS
                  Amplitude (µV)    Normal
                 ---------------    range
  Responses       OD        OS     (95% CI)
--------------   -----     -----   -------
Rod b-wave       257       275     175-471
Maximum a-wave   275       289     275-481
Maximum b-wave   444       469     414-778
Cone a-wave       23.9      24.3    45-113
Cone b-wave       94.3      91.1    99-237
Patient II:1 in family B had normal rod responses and mildly re-
duced cone responses.
332served in human chondroadherin, the closest member of the
small leucine rich protein (SLRP) gene family [18]. The
Cys48Trp mutation is a severe change at protein level with a
residue weight of -2 (Blosum80). The Arg191Gln mutation, a
Blosum80 score of +1 for this substitution, changed a charged
residue to a polar residue with otherwise similar properties.
These two mutations were not detected in 232 controls indi-
viduals of Southern Chinese ethnic origin (totally 324 X chro-
mosome from 140 males and 92 females). Neither were they
detected in previous studies nor present in the human NYX
SNP database, nor have other mutations at Cys48 or Arg191
been detected before. The mutations are unlikely to be ran-
dom occurrences since no missense changes have previously
been identified in the human NYX gene. The sequence of the
NYX coding region is very conserved: only three synonymous
variations are recorded in the SNP database, including
rs12013709, rs11798969, and rs3810733. Of these only
rs3810733 was detected in Chinese individuals analyzed in
this study. However, a c.1198G>A variation (Gly400Ser with
a Blosum 80 score of zero) was detected in 2 of the 52
probands. This variation was also detected in 5 of 232 con-
trols (3 of 140 males and 2 of 92 females) who had neither
high myopia nor had stationary night blindness. The Gly400Ser
sequence change is the first polymorphism causing an amino
acid change so far identified in NYX.
Application of the web-based method for protein fold rec-
ognition using 1D and 3D sequence profiles coupled with sec-
ondary structure and solvation potential information (3D-
PSSM) yielded the Nogo receptor as the best match to the
NYX structure (PSSM E-value=0.001222) with a sequence
identity for 285 residues of 33%. Therefore, the atomic coor-
dinates of the Nogo receptor (PDB file: 1ozn) were selected
as structural templates.
Nyctalopin adopts a leucine-rich repeat (LRR) module
with concave exterior surface containing short patches of aro-
matic and arginine residues, as does the Nogo receptor (Fig-
ure 4A). The mutations Cys48Trp and Arg191Gln were ana-
lyzed based on homology modeling atomic models of
nyctalopin as described in the Methods section, and their lo-
cations are shown in Figure 4A. The Cys48Trp mutation
changes cysteine 48 to a hydrophobic tryptophan and will break
the disulphide bridge between Cys48 and Cys35, which stabi-
©2007 Molecular Vision Molecular Vision 2007; 13:330-6 <http://www.molvis.org/molvis/v13/a36/>
Figure 3. ERG recordings of indi-
vidual II:1 in family B and that of a
representative control (N).  Normal
rod responses and mild reduced
cone responses were shown. Scale
for each subdivision: C1, C2:
200uV; D1, D2: 200uV; H1, H2:
50uV; I1, I2: 100uV; L1, L2: 100uV.
333lizes the structure of the beta-finger located in the N-terminal
cap domain (Figure 4B). Arginine 191 is located on the sur-
face of nyctalopin and forms the inter-side chain hydrogen
bond between the Ne and OD1 atoms of Arg191 and Asp168,
respectively (Figure 4C). Changing Argenine 191 to Glutamine
will break this hydrogen bond and might be expected to dis-
rupt the concave exterior surface of the molecule. While this
analysis is not definitive, it does suggest that both the Cys48Trp
and Arg191Gln mutations are likely to destabilize specific parts
of nyctalopin significantly without resulting in a complete loss
of structure.
The Arg191Gln mutation is situated in a position differ-
ent from all the missense mutations known to cause CSNB1
(Figure 5). This mutation is located within the sixth repeat of
leucine-rich repeat in NYX (LRR6), one of two loops carry-
ing additional amino acid sequences [18]. To date, the func-
tional property of these two modified loops is not known but
mutations at these additional sequences have not been previ-
ously identified. The Cys48Trp mutation occurs in the last
cysteine of the N-terminal cysteine cluster,
Cx3Cx3CxCx6Cx3C [18]. A missense mutation at the second
cysteine of this cluster, Cys31Ser, resulted in CSNB1 [19].
Current knowledge of nyctalopin is not sufficient to provide
an explanation of the different phenotypes resulting from the
Cys31Ser and Cys48Trp mutations. However, different muta-
tions in a single gene causing such varied phenotypes as pro-
gressive retinitis pigmentosa or stationary night blindness have
been described previously, including PDE6B (OMIM 180072),
RHO (OMIM 180380), and SAG (OMIM 181031). The high
myopia seen in CSNB1 is gene-specific rather than associ-
ated with night blindness in general. Night blindness, progres-
sive or stationary, has been observed in a number of diseases,
but high myopia is not always associated with such diseases
except for those resulted from mutations in RP2 and NYX.
Retinal electrophysiology studies have revealed that the
functional defects in CSNB1 involve retinal ON-pathways of
rod and cone signals [38]. Such abnormal ON-responses were
also observed in congenital stationary night blindness associ-
ated with mutations in the GRM6 gene [39]. It is interesting
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Figure 4. Structural model of
nyctalopin built by homology mod-
eling and effect of genetic muta-
tions.  A: 3-Dimensional structure
of nyctalopin. Yellow arrows show
beta-strands. The side chains of C48
and R191 are shown in red. B: De-
tail of the region surrounding the
C48W mutation showing disruption
of disulfide bonds. C: Detail of the
effect of the R191Q mutation show-
ing loss of hydrogen bonds. The
normal and mutated nyctalopin
structures are shown in red and
green, respectively. Hydrogen and
disulphide bonds are shown by
green dashed and yellow solid lines,
respectively.
Figure 5. Diagram of nyctalopin with missense mutations identified
so far (Other mutations causing null alleles were not listed here).
Nyctalopin has an NH2-terminal signal sequence, NH2-terminal cys-
teine cluster, 11 central LRRs (circles), a COOH-terminal cluster, a
region before GPI, and a GPI-anchor site. Two small circles are put
on LRR5 and LRR6, indicating the two small loops inside the nycta-
lopia as suggested [18]. The two mutations described here are shown
on the top of the protein diagram and those mutations previously
reported on the bottom.
334that two of the three patients with GRM6 mutations had mod-
erate myopia and one individual with two mutations in one
GRM6 allele had high myopia [39]. There are two parallel
ON-pathways in response to rod or cone signals [40]. While
the above correlations are certainly not definitive evidence,
they do suggest that aberrations in the cone signal resulting
from mutations in GRM6 and NYX might participate in myo-
pia formation. It has been demonstrated that blurred visual
images can induce myopia [1,41,42]. Such images might ini-
tially create a “noisy” or aberrant retinal signal before the lo-
cal eye or central nervous system can react to the retinal blur.
Similarly, variations in proteins acting in signal transmission
might also create a “noisy” or aberrant retinal signal mimick-
ing the effects of retinal blur and therefore induce myopia for-
mation. While local changes in metabolic conditions or scleral
growth and development seem likely to contribute directly,
further analysis of the retinal ON-pathway for non-syndromic
high myopia, whether transmitted autosomally or as an X-
linked trait, might provide additional clues for understanding
the molecular basis of myopia.
In summary, the results presented here suggest that muta-
tions in the NYX gene may cause isolated high myopia with-
out associated night blindness. This further suggests that distur-
bances in the retinal ON-pathway might lead to myopia and
provides a useful clue in the search for genes responsible for
high myopia as well as elucidating additional functional prop-
erties of nyctalopin.
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